雷贝拉唑钠(Rabeprazole Sodium) - 药物靶点：Proton pump_在研适应症：幽门螺杆菌感染，螺杆菌感染，胃溃疡_专利_临床

A Phase 1, Open-label, Randomized, Four-way Crossover Study to Assess the Relative Bioavailability of Two Phase 3 LY4100511 (DC-853) Tablet Formulations Compared With the Phase 2 LY4100511(DC-853) Tablet Formulation, With and Without a Proton Pump Inhibitor in Healthy Participants

The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.

开始日期2025-04-08

申办/合作机构

Eli Lilly & Co.

NCT06899061

/ Recruiting临床1期

A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies

A Phase I modular study to assess the effect of oral saruparib on other treatments in patients with advanced solid malignancies

开始日期2025-03-25

申办/合作机构

AstraZeneca PLC

[+1]

ITMCTR2025000605

/ Recruiting临床4期IIT

Randomized double-blind parallel-controlled multi-center clinical study of Ganhaiweikang capsule combined with Rabeprazole in the treatment of reflux esophagitis

开始日期2025-03-21

申办/合作机构-

100 项与雷贝拉唑钠相关的临床结果

登录后查看更多信息

100 项与雷贝拉唑钠相关的转化医学

登录后查看更多信息

100 项与雷贝拉唑钠相关的专利（医药）

登录后查看更多信息

2,535

项与雷贝拉唑钠相关的文献（医药）

2025-06-01·Sustainable Chemistry and Pharmacy

Determination of pKa values of some proton pump inhibitors in water-organic solvent mixtures: Conventional and green RPLC methods

作者: Daldal, Y. Dogan ; Demiralay, Ebru Cubuk

In this study, the ionization/protonation constants (pK_a) of commonly used proton pump inhibitors (PPIs), omeprazole, pantoprazole, rabeprazole and lansoprazole, were determined using green reversed phase liquid chromatog. (green RPLC) and conventional RPLC methods.Qual. determination of the compounds was carried out on a Gemini NX C18 (250 x 3.0 mm I.D., 5μm) column at 37°C column temperature and 1 mL/min flow rate.To determine this physicochem. parameter, liquid chromatog. analyzes of PPIs were carried out in water-organic solvent binary mixtures containing 20%, 25%, 30%, and 35% (volume/volume) of organic solvent (acetonitrile, methanol, ethanol).The effects of substituents on the pyridine and benzimidazole rings in the structures of these compounds on the pK_a values were also investigated.The pK_a(wwpK_a) values of the compounds in water environment were calculated and compared using the sspKa values in water-organic solvent mixtures and solvent macroscopic constantsThe obtained data were evaluated with AGREE and GAPI software programs that give the greenness profile, and the optimum separation condition for the green RPLC approach based on the 12 principles of green chem. was determined

2025-04-20·Journal of Audiology and Otology

Preliminary Analysis of Drug-Induced Ototoxicity in South Korea: Trends From a National Sample Dataset

Article

作者: Seo, Young Joon ; Yoon, Chul Young ; Aldahan, Zahra ; Kim, Jiwon ; Park, Kyoung Ho

Background and Objectives: Certain medications are associated with ototoxicity. This study assesses drug-induced ototoxicity in South Korea by analyzing the Korean national health data. Subjects and Methods: Hospital records of National Health Insurance members from 2009 to 2016 were reviewed. Data were compared between patients with and without hearing loss (HL). Individuals with HL were identified as having a primary diagnosis code for sensorineural HL or another type of HL in at least one outpatient or inpatient record according to the International Classification of Diseases-10. Results: The members in the HL group increased slightly from 0.8% to 1.0% relative to the total sample, compared with 99.2% to 99.0% among the controls. The proportion of males in the HL group ranged from 45.6% to 47.6%, compared with 48.4% to 48.8% among the controls. The proportion of those aged ≥65 years in the HL group increased from 34.1% to 41.4%, compared with 10.6% to 13.3% among the controls. Hypertension prevalence (24.7%-25.7%) in the HL group was higher than that in the control group (12%-12.6%). Diabetes prevalence in the HL group was 10.6%-12.3%, compared with 4.4%-5.9% among the controls. The use of proton pump inhibitor components increased, particularly esomeprazole magnesium trihydrate and rabeprazole sodium, whereas the usage of pantoprazole sodium sesquihydrate and revaprazan was high initially but declined subsequently. The usage of painkillers such as acetaminophen, loxoprofen sodium, and ibuprofen remained high, and antibiotics such as cephalosporins indicated the highest usage. However, the use of penicillin antibiotics such as amoxicillin decreased significantly. Anticancer agents showed relatively low usage compared with other drug categories, whereas antihistamines showed extremely high usage across all years, with a continual increase. Conclusions: These correlations and the underlying mechanisms necessitate further investigation, as several medicines have been linked to an increased risk of HL.

2025-04-01·Nature Chemistry

Site-specific activation of the proton pump inhibitor rabeprazole by tetrathiolate zinc centres

Article

作者: Espinet, Elisa ; Miller, Aubry K ; Marker, Teresa ; Perez-Borrajero, Cecilia ; Simon, Bernd ; Trumpp, Andreas ; Luzarowski, Marcin ; Hartmann, Eric ; Pastor-Flores, Daniel ; Steimbach, Raphael R ; Schleich, Sibylle ; Teleman, Aurelio A ; Gräter, Frauke ; Dick, Tobias P

Abstract:

Proton pump inhibitors have become top-selling drugs worldwide. Serendipitously discovered as prodrugs that are activated by protonation in acidic environments, proton pump inhibitors inhibit stomach acid secretion by covalently modifying the gastric proton pump. Despite their widespread use, alternative activation mechanisms and potential target proteins in non-acidic environments remain poorly understood. Employing a chemoproteomic approach, we found that the proton pump inhibitor rabeprazole selectively forms covalent conjugates with zinc-binding proteins. Focusing on DENR, a protein with a C4 zinc cluster (that is, zinc coordinated by four cysteines), we show that rabeprazole is activated by the zinc ion and subsequently conjugated to zinc-coordinating cysteines. Our results suggest that drug binding, activation and conjugation take place rapidly within the zinc coordination sphere. Finally, we provide evidence that other proton pump inhibitors can be activated in the same way. We conclude that zinc acts as a Lewis acid, obviating the need for low pH, to promote the activation and conjugation of proton pump inhibitors in non-acidic environments.

308

项与雷贝拉唑钠相关的新闻（医药）

2025-06-16

·米内网

第十一批集采6个消化溃疡药出击！市场跌破260亿，罗欣封王，扬子江、青峰冲上TOP20

精彩内容消化溃疡已成为临床常见病，相关药物的需求量正在不断上升，然而受到集采降价的连番重创，治疗与胃酸分泌相关疾病的药物市场“五连跌”，2024年仅剩不到260亿元。2025年至今陆续有53个新产品获批，而备战第十一批集采的产品也升至6个，新一轮市场“混战”如箭在弦。公立医院终端、公立基层医疗终端两大品牌榜单出炉，丽珠、罗欣分别夺冠，扬子江、方盛、青峰新晋TOP20品牌。87亿大品种陨落了，6个热销产品备战第十一批集采2020年起，国家集采逐步向治疗与胃酸分泌相关疾病的药物市场“下刀”，多个超10亿大品种“惨遭屠戮”，百亿市场整体规模也在逐步缩水。表1：前十批集采已中标的治疗与胃酸分泌相关疾病的药物注：销售额低于1亿元用*表示来源：米内网中国公立医疗机构终端竞争格局“有人起高楼，有人楼塌了”，奥美拉唑肠溶胶囊、艾司奥美拉唑镁肠溶片、注射用泮托拉唑钠、注射用艾司奥美拉唑钠、注射用兰索拉唑、注射用奥美拉唑钠这6个昔日超10亿大品种，经历集采后到2024年仅剩亿元级别。其中，缩水最多的是注射用泮托拉唑钠，该产品2016年曾达到峰值87亿元以上，随后出现下滑态势，2019年跌至66亿元水平，2021年纳入集采当年也有接近20亿元的销售额，随着集采影响持续扩大，2024年仅剩5.4亿元。而艾司奥美拉唑镁肠溶胶囊则是被集采带飞的特例之一，该产品在2020年首次在国内面世，广东东阳光药业为国内首仿+首家过评。2021年2月第四批集采将其纳入，广东东阳光药业、正大天晴药业集团、石药欧意药业3家企业中标。2021年该产品在中国公立医疗机构终端的销售额一举突破2.4亿元，随后持续增长91.44%、25.89%、12.01%，2024年销售额涨至6.7亿元，3家中标企业已成为该产品TOP3企业，合计市场份额超过98%，可见集采助力也可以相当勇猛。表2：目前竞争企业≥7家（原研+过评）的治疗与胃酸分泌相关疾病的药物注：标红为原研企业，统计截至2025年6月15日来源：米内网中国上市药品（MID）数据库6个产品目前竞争企业在7家及以上，其中法莫替丁注射液（5亿+）、富马酸伏诺拉生片（7亿+）、瑞巴派特片（8亿+）、西甲硅油乳剂（4亿+）分别是治疗与胃酸分泌相关疾病的药物市场的TOP19、TOP13、TOP11、TOP21产品。90多家药企集团（二级）蓄势待发，福安药业、辰欣药业等6家集团有两个产品备战，石家庄四药、人福医药、齐鲁制药、鲁南制药、科伦药业等85家集团有1个产品备战，集中度不算太高，最终还是靠企业各显神通。丽珠、罗欣领跑TOP20品牌，扬子江、方盛、青峰新上榜细分终端，公立医院终端（城市公立医院+县级公立医院）2024年治疗与胃酸分泌相关疾病的药物销售额跌至225亿元，降幅在7.41%，其中质子泵抑制剂降幅超过10%、H2-受体阻滞剂降幅超过9%。表3：2024年中国公立医院终端治疗与胃酸分泌相关疾病的药物TOP20品牌（单位：亿元）来源：米内网中国公立医疗机构终端竞争格局丽珠集团丽珠制药的注射用艾普拉唑钠和艾普拉唑肠溶片继续占领TOP1、TOP2品牌宝座，2024年在中国公立医院终端的销售额均超过10亿元。两大品牌首次冲上TOP20榜单：德国柏林化学的西甲硅油乳剂2021-2024年连续增长了69.71%、28.61%、12.73%、8.12%，品牌排名从2021年的TOP36一路飞升至2024年的TOP17；青峰医药旗下江西山香药业的艾司奥美拉唑镁肠溶片2020年获批上市，2021-2024年连续增长了47374.87%、96.57%、14.98%、9.57%，品牌排名从2022年的TOP27一路飞升至2024年的TOP20。公立基层医疗终端（城市社区中心+乡镇卫生院）2024年治疗与胃酸分泌相关疾病的药物销售额跌至34亿元，降幅在7.60%，比公立医院终端的情况更为严峻，其中质子泵抑制剂、H2-受体阻滞剂的降幅均超过10%。表4：2024年中国公立基层医疗终端治疗与胃酸分泌相关疾病的药物TOP20品牌（单位：亿元）注：销售额低于1亿元用*表示来源：米内网中国公立医疗机构终端竞争格局4大品牌销售额超过1亿元：山东罗欣药业集团的奥美拉唑肠溶胶囊首次登上榜首，2024年销售额保持在1.6亿元水平；成都倍特药业的盐酸雷尼替丁注射液2024年销售额达1.5亿元，品牌排名上升1位至TOP2；上海现代制药旗下现代哈森(商丘)药业的盐酸雷尼替丁注射液、济川药业集团的雷贝拉唑钠肠溶胶囊2024年销售额均超过1.4亿元。4个品牌首次冲进TOP20榜单：昆明积大制药的硫糖铝混悬凝胶2021-2024年连续增长了27.28%、4.19%、25.32%、30.94%，品牌排名从2021年的TOP42一路飞升至2024年的TOP14；遂成药业的盐酸雷尼替丁注射液2021-2024年连续增长了364.40%、21.81%、51.79%、7.37%，品牌排名从2022年的TOP47一路飞升至2024年的TOP18；扬子江四川海蓉药业的兰索拉唑肠溶片2023-2024年连续增长了7.51%、5.95%，品牌排名从2023年的TOP26跃升至2024年的TOP19；湖南方盛制药的奥美拉唑肠溶片2022-2024年连续增长了891.11%、5.39%、12.45%，品牌排名从2022年的TOP37一路飞升至2024年的TOP20。市场首次跌破260亿，53个新品“谷底捞金”在中国公立医疗机构终端（城市公立医院+县级公立医院+城市社区中心+乡镇卫生院），治疗与胃酸分泌相关疾病的药物在2013-2019年保持稳步增长，2019年峰值为425亿元。2020年1月第二批国家集中带量采购启动，铝碳酸镁咀嚼片成为首个纳入集采的治疗与胃酸分泌相关疾病的药物，从此这个热销百亿市场开始走下坡路。图1：中国公立医疗机构终端治疗与胃酸分泌相关疾病的药物销售情况（单位：万元）来源：米内网中国公立医疗机构终端竞争格局2020年第二批和第三批集采共纳入3个产品，2021年第四批和第五批集采共纳入6个产品，2022年第七批集采纳入1个产品，2023年第九批集采纳入4个产品，2024年第十批集采纳入1个产品，2025年即将启动的第十一批集采已有6个产品备战……国家集采持续搅局治疗与胃酸分泌相关疾病的药物市场，该类药物的销售额从2020年开始“五连跌”，到了2024年跌至259.6亿元，是近12年新低。然而，随着消化溃疡的发病率持续上升，相关药物的需求量也在不断增加，依然吸引到了众多药企加码布局，或者成为市场新的掘金者。表5：2025年至今获批的治疗与胃酸分泌相关疾病的药物新产品来源：米内网中国申报进度（MED）数据库截至2025年6月15日，今年以来已累计有53个治疗与胃酸分泌相关疾病的药物新产品获批上市（按产品名+企业统计），均为仿制药，法莫替丁注射液和富马酸伏诺拉生片成为了热门产品，获批企业分别达到了13家、12家。同时，市场也迎来了新一批掘金者，成都欣捷高新、云南先施药业、湖南先施制药、江西施美药业、北京北陆药业、广州新济药业、湖南银泽华浩生物科技、江苏中邦制药、湖北邦泽医药、成都归合科技、成都米子生物医药科技、海南慧通生物医药科技、苏州朗易生物医药研究、呋欧医药14家药企是首次有治疗与胃酸分泌相关疾病的药物获批。资料来源：米内网数据库注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至6月15日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

带量采购核酸药物

2025-06-02

·eisai.com

Eisai to Launch “Pariet® S,” the First Proton Pump Inhibitor RX-to-OTC in Japan

For Print June 2, 2025 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the launch of “Pariet® S” (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn and stomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan. 1 "Pariet S" is the first proton pump inhibitor (PPI 2) to receive manufacturing and marketing approval as an over the counter (OTC) medicine in Japan. Rabeprazole sodium, in an amount equivalent to that used in the prescription product 3, works directly on the proton pumps that produce stomach acid, effectively alleviating severe heartburn caused by gastric acid reflux and stomach pain due to excessive acid secretion. The medicine comes in small, easy-to-swallow tablets, with a once-daily dosage providing 24-hour relief. Rabeprazole sodium, the active ingredient in “Pariet S”, is a PPI developed at Eisai’s Tsukuba Research Laboratories. The medicine was first launched in Japan in 1997 as a prescription pharmaceutical under the brand name “Pariet” and has since been approved more than 100 countries worldwide. It is widely prescribed to people struggling with acid-related disorders. In recent years, there is a tendency for increased stomach acid secretion due to disrupted eating habits, stress, and a decline in the infection rate of Helicobacter pylori. Moreover, the number of individuals experiencing gastric acid reflux has grown, driven by age-related weakening of the lower esophageal sphincter. Eisai will introduce “Pariet S” as a new treatment option in the OTC gastric medication market, aiming to alleviate sever heartburn and discomfort caused by gastric acid related conditions, and strongly support people in the daily living domain who wish for a comfortable and secure daily life. For further details, please refer to the product’s website for details about "Pariet S" (Japanese only) https://www.eisai.jp/products/pariet/pariets 1 "Pariet S" is classified as a drug that requires a pharmacist’s guidance at the time of sale 2 Proton Pump Inhibitor suppresses gastric acid secretion by inhibiting the “proton pump” which is the final step in the secretion process. 3 Contains rabeprazole10mg per tablet Media Inquiries: Public Relations Department, Eisai Co., Ltd. +81-(0)3-3817-5120 [Notes to editors] Product Outline 1. Product Name: “Pariet® S” (RX-to-OTC switch, pharmaceutical requiring guidance) 2. Ingredients: Per daily dose of one tablet: rabeprazole sodium 10mg Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate 3. Indications and Usage: Stomach pain, heartburn, and bloating (This medicine contains a proton pump inhibitor which suppresses stomach acid secretion.) 4. Dosage and Administration: Adults (15 years and older): 1 tablet once daily. Do not use this medicine consecutively for more than two weeks. 5. Packaging and Recommended Retail Price (excluding tax): Packaging: 6 tablets, Recommended retail price: 1,480 yen 6. Manufactured and marketed by: Eisai Co., Ltd. Inactive Ingredients: Magnesium oxide, talc, hydroxy propyl cellulose, D-mannitol, ethylcellulose, carnauba wax, carmellose calcium, glycerin esters of fatty acids, titanium oxide, iron sesquioxide, magnesium stearate, hypromellose phthalate Full text

上市批准

2025-05-21

·米内网

【聚焦】8亿畅销产品，罗欣药业入局抢食

精彩内容近日，罗欣药业旗下山东裕欣药业提交了富马酸伏诺拉生片的4类仿制上市申请，该产品是治疗与胃酸分泌相关疾病的畅销药物，2024年在中国三大终端六大市场（统计范围见文末）的销售额超过8亿元。在该类药物市场，罗欣药业为TOP4集团（一级），新品上市有望进一步提升公司的市场竞争力。图1：山东裕欣药业最新申报的产品来源：CDE官网富马酸伏诺拉生片用于治疗反流性食管炎，以及与适当的抗生素联用以根除幽门螺杆菌，米内网数据显示，目前该产品的竞争格局（原研+国产）已超过10家。图2：富马酸伏诺拉生片的销售情况（单位：万元）来源：米内网格局数据库近几年在中国三大终端六大市场，富马酸伏诺拉生片的销售额一路狂飙，2024年涨至接近8.3亿元，为近五年峰值。在治疗与胃酸分泌相关疾病的药物市场，富马酸伏诺拉生片已跃升为TOP15产品。从渠道来看，公立医院终端（城市公立医院+县级公立医院）依然是富马酸伏诺拉生片的销售主阵地，而该产品在零售药店终端（城市实体药店+网上药店）近两年的增速高达553.35%、42.96%，潜力不容小觑。2024年在中国三大终端六大市场，罗欣药业是治疗与胃酸分泌相关疾病的药物TOP4集团（一级），公司在该类药物市场的过亿产品包括了替戈拉生片（1类新药）、注射用雷贝拉唑钠、奥美拉唑肠溶胶囊等。表1：2024年罗欣药业的治疗与胃酸分泌相关疾病的药物销售正增长的产品来源：米内网格局数据库表2：2023年至今罗欣药业（含子公司）获批的新品（不含2.4类）来源：米内网中国申报进度（MED）数据库2023年至今，罗欣药业陆续获批了盐酸乌拉地尔注射液、利伐沙班片、盐酸伐昔洛韦片、雷贝拉唑钠肠溶片和盐酸左沙丁胺醇雾化吸入溶液，其中雷贝拉唑钠肠溶片为公司在治疗与胃酸分泌相关疾病的药物市场再添重磅一员。资料来源：CDE官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至5月21日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准一致性评价生物类似药

100 项与雷贝拉唑钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00724	雷贝拉唑钠	A02BC04	DBSALT000552

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
幽门螺杆菌感染	美国	Aytu Biopharma, Inc.	2013-03-26
螺杆菌感染	韩国	Genuone Sciences, Inc.	2000-02-21
胃溃疡	韩国	Genuone Sciences, Inc.	2000-02-21
十二指肠溃疡	美国	Waylis Therapeutics LLC	1999-08-19
胃食管反流	美国	Waylis Therapeutics LLC	1999-08-19
吻合口溃疡	日本	Eisai Co., Ltd.	1997-10-14
反流性食管炎	日本	Eisai Co., Ltd.	1997-10-14
非糜烂性胃食管反流病	日本	Eisai Co., Ltd.	1997-10-14
Zollinger-Ellison综合征	日本	Eisai Co., Ltd.	1997-10-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
上消化道出血	临床3期	中国	江苏奥赛康药业有限公司	2017-01-18
喉炎	临床3期	美国	Pricara	2003-08-01
喉咽反流	临床3期	美国	Pricara	2003-08-01
非糜烂性反流病	临床3期	-	Janssen Pharmaceutica NV	2001-10-01
哮喘	临床3期	美国	Pricara	2000-10-01
局部晚期恶性实体瘤	临床2期	法国	Institut de Recherches Intern Servier	2010-07-01
局部晚期恶性实体瘤	临床2期	意大利	Institut de Recherches Intern Servier	2010-07-01
局部晚期恶性实体瘤	临床2期	西班牙	Institut de Recherches Intern Servier	2010-07-01
良性胃溃疡	临床1期	中国	湖南明瑞医药有限责任公司	2018-05-08
良性胃溃疡	临床1期	中国	北京华睿鼎信科技有限公司	2018-05-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


DDW2024	N/A	一线	720	14-day vonoprazan triple therapy	窪壓膚鑰築積選願餘齋(積窪製遞鏇憲襯蓋衊廠) = 選膚憲齋獵衊構積壓糧窪鏇網憲鏇築鏇鏇餘製 (鹹淵廠繭鬱鏇夢餘襯夢, 90.1 ~ 96.5)	积极	2024-05-18
				14-day vonoprazan high-dose dual therapy	窪壓膚鑰築積選願餘齋(積窪製遞鏇憲襯蓋衊廠) = 構觸鹽製齋窪壓選醖膚窪鏇網憲鏇築鏇鏇餘製 (鹹淵廠繭鬱鏇夢餘襯夢, 82.0 ~ 90.6)
UEGW2018	N/A	胃食管反流	-	Dexrabeprazole 10 mg	鹹餘糧範壓憲憲窪獵鑰(積鹽選膚繭壓醖齋鬱獵) = 衊齋築觸網鬱窪艱願蓋顧廠鹹餘顧選衊選製鏇 (願鑰顧遞鑰遞憲鑰獵衊 ) 更多	-	2018-10-01
NCT02605395 (CTgov)	临床4期	胃肠道疾病	70	Idiazole (Idiazole 20 mg)	壓廠醖窪壓築廠醖夢淵(選築顧築齋遞願餘壓積) = 顧選壓鹽壓窪鑰憲壓積憲簾壓廠選膚糧鹹選顧 (餘遞壓廠鏇鑰憲餘築糧, 158.60) 更多	-	2018-10-01
				Pariet (Pariet 20 mg)	壓廠醖窪壓築廠醖夢淵(選築顧築齋遞願餘壓積) = 繭繭壓醖顧積鹽艱壓簾憲簾壓廠選膚糧鹹選顧 (餘遞壓廠鏇鑰憲餘築糧, 179.24) 更多
NCT02446483 (CTgov)	临床4期	胃肠道疾病	60	Rabeprazole (Treatment A- Rabeprazole 20 mg)	衊夢鬱淵繭鑰壓夢衊壓(醖觸淵鹽齋蓋簾鑰壓構) = 積簾襯膚製蓋鹹憲蓋衊壓憲夢範廠構鹹衊遞範 (衊網築顧繭構鹹鑰夢醖, 35.67) 更多	-	2017-06-14
				Rabeprazole (Treatment B- Rabeprazole 20 mg)	衊夢鬱淵繭鑰壓夢衊壓(醖觸淵鹽齋蓋簾鑰壓構) = 鏇鏇鬱艱廠壓窪淵廠餘壓憲夢範廠構鹹衊遞範 (衊網築顧繭構鹹鑰夢醖, 32.98) 更多
NCT00911534 (CTgov)	临床3期	胃食管反流	305	placebo (Placebo)	鏇醖鏇襯壓遞艱衊構夢(衊憲遞窪願糧獵醖簾鬱) = 範餘顧醖餘鹹製繭積餘壓製淵製鑰膚衊範製艱 (鹽築觸憲廠築蓋築選鑰, 26.8) 更多	-	2016-02-02
				RAB ER (RAB ER 50mg)	鏇醖鏇襯壓遞艱衊構夢(衊憲遞窪願糧獵醖簾鬱) = 膚艱製齋構壓鹽廠廠選壓製淵製鑰膚衊範製艱 (鹽築觸憲廠築蓋築選鑰, 34.49) 更多
NCT00658775 (CTgov)	临床3期	胃食管反流	1,069	ESO (ESO 40mg)	顧鹹鬱繭蓋廠選鹽願餘 = 遞衊獵製積觸觸廠餘憲糧憲艱壓餘觸餘壓構築 (鹹窪網鬱廠網築網鬱簾, 醖夢襯壓築鏇遞鬱衊醖 ~ 鏇廠鏇鬱繭襯鬱糧窪鹹) 更多	-	2015-06-23
				placebo (RAB ER 50mg)	顧鹹鬱繭蓋廠選鹽願餘 = 繭構廠遞簾築醖遞窪簾糧憲艱壓餘觸餘壓構築 (鹹窪網鬱廠網築網鬱簾, 蓋鑰襯壓窪願觸遞醖鑰 ~ 夢齋範範艱廠鹹衊廠鹽) 更多
NCT00658632 (CTgov)	临床3期	胃食管反流	1,397	ESO (ESO 40 mg)	願醖鑰鬱憲衊蓋鏇醖顧 = 選襯觸構簾選構衊鏇壓觸簾醖壓餘範廠艱憲築 (鏇積蓋製夢鹽範餘襯簾, 衊選獵艱積獵範糧鬱願 ~ 選廠憲繭繭齋築醖廠衊) 更多	-	2015-06-23
				placebo+ESO (RAB ER 50 mg)	願醖鑰鬱憲衊蓋鏇醖顧 = 築壓壓製簾願簾襯簾鬱觸簾醖壓餘範廠艱憲築 (鏇積蓋製夢鹽範餘襯簾, 觸膚網餘窪範製觸糧繭 ~ 夢積鏇餘餘觸網獵鬱範) 更多
NCT00658528 (CTgov)	临床3期	胃食管反流	1,061	ESO (ESO 40 mg)	鹹膚獵顧觸鹹鹽淵廠積 = 簾衊範鹽壓願鹽構鏇構鏇艱製製襯製夢鹹夢糧 (範壓齋醖壓餘鑰鹽壓窪, 廠範顧觸築糧糧築窪夢 ~ 窪顧壓衊獵繭選鹹範鏇) 更多	-	2015-06-23
				placebo+ESO (RAB ER 50 mg)	鹹膚獵顧觸鹹鹽淵廠積 = 繭遞願襯鏇壓構齋簾憲鏇艱製製襯製夢鹹夢糧 (範壓齋醖壓餘鑰鹽壓窪, 壓鏇鹽蓋獵鹽糧餘淵壓 ~ 壓築憲築膚繭餘積夢範) 更多
NCT01397448 (CTgov)	临床2/3期	胃溃疡	472	Teprenone	鹹範鏇範選廠糧遞壓鬱 = 醖膚觸顧顧艱夢選淵糧簾餘遞範選憲範齋夢餘 (鹹壓艱糧鬱構憲遞網鏇, 製廠壓鏇廠窪壓製糧淵 ~ 積選艱襯鹹選鬱鏇壓獵) 更多	-	2014-10-23
NCT00992589 (Pubmed \| J Pediatr Gastroenterol Nutr)	临床3期	胃食管反流	344	Placebo	醖廠醖鬱艱築鏇網衊鹽(廠積憲艱繭鏇醖醖夢憲) = 鏇餘窪齋襯選選膚壓醖糧鑰鹽製網膚觸壓夢築 (繭膚觸憲糧構餘艱襯襯 ) 更多	-	2014-02-01
				Rabeprazole 5 mg	醖廠醖鬱艱築鏇網衊鹽(廠積憲艱繭鏇醖醖夢憲) = 積廠積鹽願顧鏇鹹窪壓糧鑰鹽製網膚觸壓夢築 (繭膚觸憲糧構餘艱襯襯 ) 更多